Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
- PMID: 11130391
- DOI: 10.1016/S0140-6736(00)03266-9
Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
Abstract
Further well designed studies are urgently needed to clarify if use of prostate-specific antigen (PSA) as a diagnostic test for prostate cancer can be improved by incorporating measurements of serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding-protein 3 (IGFBP-3), and if these measurements might also identify men at higher risk.
Comment in
-
Prostate cancer screening.Lancet. 2001 Apr 14;357(9263):1201; author reply 1201-2. doi: 10.1016/S0140-6736(00)04340-3. Lancet. 2001. PMID: 11330269 No abstract available.
-
Prostate cancer screening.Lancet. 2001 Apr 14;357(9263):1201-2; author reply 1201-2. doi: 10.1016/s0140-6736(00)04341-5. Lancet. 2001. PMID: 11332425 No abstract available.
-
Prostate cancer screening.Lancet. 2001 Apr 14;357(9263):1202-3. doi: 10.1016/S0140-6736(00)04344-0. Lancet. 2001. PMID: 11332426 No abstract available.
-
Prostate cancer screening.Lancet. 2001 Apr 14;357(9263):1202. doi: 10.1016/S0140-6736(00)04343-9. Lancet. 2001. PMID: 11379564 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
